Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment

Atherosclerosis

Volumn 126, Issue 2, 1996, Pages 305-312

  Leitinger, Norbert ^a   Pirich, Christian ^b   Blazek, Ingrid ^b   Endler, Georg ^b   Sinzinger, Helmut ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atherosclerosis; Dextrane sulfate LDL apheresis; Isoprostanes; LDL oxidation; Thiobarbituric acid reactive substances

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; AUTOANTIBODY; DEXTRAN SULFATE; LOW DENSITY LIPOPROTEIN; PROSTAGLANDIN DERIVATIVE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ADULT; APHERESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROPHORESIS; FEMALE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TECHNIQUE;

EID: 0030601707     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05919-9     Document Type: Article

References (27)

1. Steinberg D, Parathasarathy S, Carew TE, Khoo JC Beyond cholesterol. Modifications of low-density lipoproteins that increase their atherogenicity. N Engl J Med. 320:1989;915-924.
2. Goldstein JL, Brown MS The low density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Biochem. 46:1977;897-930.
3. Ylä-Herttuala S, Palinski W, Rosenfeld MEet al. Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 84:1989;1086-1095.
4. Lita T, Nagano Y, Yokode Met al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipemic rabbit, an animal model for familial hyperlipidemia. Proc Natl Acad Sci USA. 84:1987;5928-5931.
5. Maggi E, Finardi G, Poli Met al. Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coronary Artery Disease. 4:1993;1119-1122.
6. Salonen JT, Ylä-Herttuala S, Yamamoto Ret al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-886.
7. Maggi E, Bellazi R, Ravetta V, Falaschi F, Finardi G, Bellomo G Low-density lipoprotein oxidation in essential hypertension. J Hypertens. 11:1993;1103-1111.
8. Maggi E, Bellazi R, Falaschi Fet al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int. 45:1994;876-883.
9. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical catalyzed mechanism. Proc Natl Acad Sci USA. 87:1990;9383-9387.
10. 2-isoprostanes during oxidative modification of low-density lipoprotein. Biochem Biophys Res Commun. 200:1994;338-343.
11. Mathews WR, Guido DM, Fisher MA, Jaeschke H Lipid peroxidation as molecular mechanism of liver cell injury during reperfusion after ischemia. Free Rad Biol Med. 16:1994;763-770.
12. Morrow JD, Moore KP, Awad JAet al. Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome. J Lipid Mediat. 6:1993;417-420.
13. Ernst E LDL-apheresis: a new option to influence blood rheology. Thromb Haem Dis. 1:1991;31-37.
14. Sinzinger H, Pirich C, Bednar J, O'Grady J LDL-apheresis improves in-vitro and in-vivo platelet function. Thromb Res. 82:1996;291-301.
15. Bröijersén A, Eriksson M, Larsson PT, Beck O, Berglund L, Angelin B, Hjerndahl P Effects of selective LDL-apheresis and pravastatin therapy on platelet function in familial hypercholesterolemia. Europ J Clin Invest. 24:1994;488-498.
16. Kroon AA, Demacker PNM, Stalenhoef AFH Lipoprotein levels and oxidizability of LDL during long-term apheresis. Atherosclerosis. 109:1994;168. (Abstract).
17. Rumsey SC, Galeano NF, Arad Y, Deckelbaum RJ Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins. J Lipid Res. 33:1992;1551-1561.
18. Havel RJ, Eder HA, Bragdon JH The distribution and chemical composition of ultracentrifugally separated lipoproteins of human serum. J Clin Invest. 43:1955;1345-1353.
19. Esterbauer H, Striegl G, Puhl H, Rothender M Continuous monitoring of in-vitro oxidation of low density lipoprotein. Free Rad Res Commun. 6:1989;67-75.
20. Wallin B, Rosengren B, Shertzer HG, Camejo G Lipoprotein oxidation and measurement of thiobarbituric acid reacting substances formation in a single microtiter plate: its use for the evaluation of antioxidants. Anal Biochem. 208:1993;10-15.
21. Tatzber F, Rabl H, Koriska K, Erhart U, Puhl H, Waeg G, Krebs A, Esterbauer H Elevated serum neopterin levels in atherosclerosis. Atherosclerosis. 89:1991;203-208.
22. Hurt-Camejo E, Camejo G, Rosengren Bet al. Effect of arterial proteoglycans and glycosaminoglycans on low-density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscl Thromb. 12:1992;569-583.
23. de Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH Enhanced susceptibility to in-vitro oxidation of low-density lipoprotein subfraction in healthy subjects. Arterioscl Thromb. 11:1991;298-306.
24. Engelmann B, Bräutigam C, Thiery J Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins. Biochem Biophys Res Com. 204:1994;1235-1242.
25. Bräutigam C, Engelmann B, Reiss D, Reinhardt U, Thiery J, Richter WO, Brosche T Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL-apheresis. Atherosclerosis. 119:1996;77-88.
26. Herman M, Gmeiner B Altered susceptibility to in-vitro oxidation of LDL in LDL complexes and LDL aggregates. Arterioscl Thromb. 12:1992;1503-1506.
27. Engelmann B, Bräutigam C, Kulschar Ret al. Reversible reduction of phospholipid bound arachidonic acid after low-density lipoprotein apheresis. Evidence for rapid incorporation of plasmalogen phosphatidylethanolamine into red blood cell membrane. Biochim Biophys Acta. 1196:1994;154-164.